Beigene Ltd ADR (ONC) Stock Price, Quote & News

Company Profile

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multic...

Industry: Biotechnology

Sector: Healthcare

Phone: 41 61 685 19 00

Website: beonemedicines.com

Address:

94 Aeschengraben 27, Basel, Switzerland

albiegf13 Aug. 19 at 12:33 AM

$IBRX Both $AMGN & $ONC hit new all time highs today...

2 · Reply

JimmyOcarri Aug. 17 at 7:56 PM

$WDC $CIEN $STRL $ONC $IAG possible

0 · Reply

MaverikIT Aug. 11 at 2:59 PM

@Jblack500 @cynicaloptimist @WAJeff @BustaCapital @IsabellaDC @No_Face_character $SE $ONC $SKHY ... $KORU

0 · Reply

BixbyKnolls Aug. 11 at 2:45 PM

$IBRX That BeOne Medicines $ONC has the Magic touch. Chart been on the move- They signed a deal for China with $RVMD. IBRX has a collaboration with $ONC -- waiting for word.

0 · Reply

Lexcol Aug. 11 at 1:52 PM

$CMPX back to 3 $ $RVMD $ONC

0 · Reply

Pika_Capital Aug. 10 at 1:45 PM

$ONC biggest position from Cost basis perspective at the moment. Firing on all cylinders. There is china stigma attached to this name still but it's slowly fading away

0 · Reply

Zephix Aug. 7 at 10:58 AM

$ONC Got more than 50 clinical and commercial programs, including promising therapies for solid tumors, BCL-2 inhibition, and antibody-drug conjugates.…

0 · Reply

EarningsInsider Aug. 5 at 3:00 PM

https://www.marketbeat.com/earnings/reports/2026-8-5-beigene-ltd-stock-1/ $ONC BeOne Medicines Earnings Transcript

0 · Reply

StocktwitsNews Aug. 5 at 2:03 PM

ONC Q2 2026 Earnings Summary $ONC https://stocktwits.com/news/earnings/earnings/onc-q2-2026-earnings-summary/cZo4s6FRJIr

0 · Reply

Pika_Capital Aug. 5 at 2:01 PM

$ONC this stock should be $500, not $330 🤡 but I have time

1 · Reply

BeOne Medicines renews partnerships to expand access to Brukinsa in leukemia

Tue, 18 Aug 2026 06:00:00 -0400 - 1 day ago

BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries

2026-08-12T15:08:27.000Z - 6 days ago

BeOne Medicines (ONC) Q2 2026 Earnings Call Transcript

2026-08-10T12:16:57.000Z - 9 days ago

BeOne Medicines price target raised to $370 from $340 at Wolfe Research

2026-08-10T10:15:22.000Z - 9 days ago

BeOne Medicines partners with Revolution Medicines for clinical development

RVMD

Mon, 10 Aug 2026 06:00:00 -0400 - 9 days ago

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration

2026-08-06T15:40:27.000Z - 12 days ago

BeOne Medicines price target raised to $405 from $395 at Morgan Stanley

2026-08-06T12:52:54.000Z - 12 days ago

BeOne Medicines price target raised to $454 from $424 at TD Cowen

2026-08-06T12:22:25.000Z - 12 days ago

BeOne Medicines price target raised to $418 from $416 at Truist

2026-08-06T10:51:43.000Z - 13 days ago

BeOne Medicines price target raised to $430 from $420 at Guggenheim

2026-08-06T10:47:11.000Z - 13 days ago

BeOne Medicines price target lowered to $450 from $451 at RBC Capital

2026-08-06T10:15:37.000Z - 13 days ago

BeOne Medicines price target raised to $466 from $453 at Citi

2026-08-06T09:50:38.000Z - 13 days ago

BeOne Medicines price target raised to $405 from $396 at Citizens

2026-08-06T09:10:29.000Z - 13 days ago

BeOne Medicines price target raised to $407 from $403 at Barclays

Wed, 05 Aug 2026 14:04:56 -0400 - 13 days ago

BeOne Medicines Q2 Earnings Call Highlights

Aug 5, 2026, 8:00 AM EDT - 14 days ago

BeOne Medicines AG Earnings Call Transcript: Q2 2026

Aug 5, 2026, 8:00 AM EDT - 14 days ago

BeOne Medicines AG Earnings release: Q2 2026

Aug 5, 2026, 8:00 AM EDT - 14 days ago

BeOne Medicines AG Quarterly report: Q2 2026

Aug 5, 2026, 8:00 AM EDT - 14 days ago

BeOne Medicines AG Slides: Q2 2026

2026-08-05T11:30:44.000Z - 14 days ago

Is BeOne Medicines Ltd (ONC) Undervalued After Q2 Earnings Beat? GAAP EPS Hits $2. ...

Wed, 05 Aug 2026 06:00:00 -0400 - 14 days ago

BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates

2026-08-04T13:15:08.000Z - 14 days ago

Countdown to BeOne Medicines Ltd. - Sponsored ADR (ONC) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS

2026-07-23T13:33:27.000Z - 26 days ago

BeOne Medicines Expands U.S. Manufacturing With $1 Billion Investment

2026-07-23T11:21:12.000Z - 27 days ago

BeOne Medicines price target raised to $425 from $415 at JPMorgan

2026-07-23T11:16:55.909Z - 27 days ago

BeOne announces $300 million expansion of US manufacturing facility

2026-07-23T10:21:26.000Z - 27 days ago

BeOne Medicines to invest $300M in New Jersey R&D center

Jul 23, 2026, 6:00 AM EDT - 27 days ago

BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines

ONC

Jul 17, 2026, 6:01 AM EDT - 4 weeks ago

BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5

ONC

2026-07-14T09:40:22.000Z - 5 weeks ago

BeOne Medicines price target lowered to $403 from $409 at Barclays

2026-07-13T01:05:04.000Z - 5 weeks ago

BeOne Medicines upgraded to Buy from Hold at Jefferies

2026-07-09T16:26:57.000Z - 5 weeks ago

BeOne Medicines (ONC) Receives FDA Orphan Designation for Pancreatic Cancer Treatment

2026-07-09T15:00:13.000Z - 5 weeks ago

BeOne Medicines treatment of pancreatic cancer granted orphan status

2026-07-07T13:16:12.000Z - 6 weeks ago

BeOne Medicines price target raised to $416 from $413 at Truist

2026-07-07T11:30:16.000Z - 6 weeks ago

BeOne Medicines price target raised to $451 from $436 at RBC Capital

2026-06-30T11:31:03.000Z - 7 weeks ago

BeOne Medicines (ONC) Reports Positive Phase 3 MANGROVE Study Results

2026-06-30T10:05:25.000Z - 7 weeks ago

BeOne Medicines’ Brukinsa shows efficacy in Phase 3 lymphoma trial

Jun 30, 2026, 6:00 AM EDT - 7 weeks ago

BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma

ONC

Jun 12, 2026, 6:00 AM EDT - 2 months ago

BeOne Medicines' Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026

ONC

2026-06-11T11:40:08.000Z - 2 months ago

BeOne Medicines announces presentation of Phase 3 data in CLL patients

Jun 11, 2026, 7:24 AM EDT - 2 months ago

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit

ONC

Jun 8, 2026, 10:00 AM EDT - 2 months ago

BeOne Medicines AG Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

2026-06-02T15:06:47.000Z - 2 months ago

BeOne Medicines price target raised to $436 from $425 at RBC Capital

Tue, 02 Jun 2026 02:09:49 -0400 - 2 months ago

BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3

Jun 1, 2026, 8:00 PM EDT - 2 months ago

BeOne Medicines AG Transcript: Study update

Jun 1, 2026, 8:00 PM EDT - 2 months ago

BeOne Medicines AG Press release: Study update

Jun 1, 2026, 8:00 PM EDT - 2 months ago

BeOne Medicines AG Slides: Study update

Jun 1, 2026, 6:34 AM EDT - 2 months ago

Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's

ONC SMMT RVMD

Jun 1, 2026, 6:00 AM EDT - 2 months ago

BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026

ONC

May 29, 2026, 6:00 AM EDT - 2 months ago

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026

ONC

2026-05-27T21:10:12.000Z - 2 months ago

BeOne Medicines’ combination shows improved survival in adenocarcinoma

May 27, 2026, 5:00 PM EDT - 2 months ago

BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026

ONC

Tue, 26 May 2026 06:01:00 -0400 - 3 months ago

BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Thu, 21 May 2026 06:00:00 -0400 - 3 months ago

BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts

Wed, 20 May 2026 06:00:00 -0400 - 3 months ago

BeOne Medicines Launches One Save Changes Everything, a Global Cancer Care Awareness Campaign with Soccer Legend Tim Howard

Wed, 13 May 2026 13:34:35 -0400 - 3 months ago

US FDA approves BeOne's drug for a type of blood cancer

Wed, 13 May 2026 13:27:00 -0400 - 3 months ago

BeOne Medicines' BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma

May 6, 2026, 8:00 AM EDT - 3 months ago

BeOne Medicines AG Earnings Call Transcript: Q1 2026

May 6, 2026, 8:00 AM EDT - 3 months ago

BeOne Medicines AG Earnings release: Q1 2026

May 6, 2026, 8:00 AM EDT - 3 months ago

BeOne Medicines AG Quarterly report: Q1 2026

May 6, 2026, 8:00 AM EDT - 3 months ago

BeOne Medicines AG Slides: Q1 2026

Wed, 06 May 2026 06:00:00 -0400 - 3 months ago

BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates

Wed, 29 Apr 2026 06:00:00 -0400 - 4 months ago

U.S. FDA Grants Priority Review to BeOne Medicines' TEVIMBRA in First-Line HER2+ GEA

Apr 28, 2026, 8:00 AM EDT - 4 months ago

BeOne Medicines AG Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

BeOne Medicines AG Proxy statement: Proxy filing

Apr 22, 2026, 6:01 AM EDT - 4 months ago

BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6

Apr 16, 2026, 8:00 AM EDT - 4 months ago

BeOne Medicines AG Proxy statement: Proxy filing

Mar 2, 2026, 9:10 AM EST - 6 months ago

BeOne Medicines AG Transcript: TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 8:00 AM EST - 6 months ago

BeOne Medicines AG Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:00 AM EST - 6 months ago

BeOne Medicines AG Annual report: Q4 2025

Feb 26, 2026, 8:00 AM EST - 6 months ago

BeOne Medicines AG Earnings release: Q4 2025

Feb 26, 2026, 8:00 AM EST - 6 months ago

BeOne Medicines AG Slides: Q4 2025

Feb 26, 2026, 6:00 AM EST - 6 months ago

BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership

Feb 17, 2026, 6:00 AM EST - 6 months ago

BeOne Medicines to Present at Upcoming Investor Conferences

Feb 11, 2026, 6:00 AM EST - 6 months ago

BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26

Jan 13, 2026, 10:30 AM EST - 7 months ago

BeOne Medicines AG Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 10:30 AM EST - 7 months ago

BeOne Medicines AG Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 6:00 AM EST - 7 months ago

BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 1:30 PM EST - 8 months ago

ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA

Dec 23, 2025, 6:01 AM EST - 8 months ago

BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 6:00 AM EST - 8 months ago

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

Dec 10, 2025, 6:00 PM EST - 8 months ago

Senhwa Biosciences and BeOne Medicines Announces a Clinical Supply Agreement to Address the Challenge of Cold Tumors

Dec 8, 2025, 8:00 AM EST - 9 months ago

BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

Dec 7, 2025, 6:00 PM EST - 9 months ago

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

$U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma$

Nov 26, 2025, 6:00 AM EST - 9 months ago

U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Nov 20, 2025, 6:00 AM EST - 9 months ago

BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025

Nov 17, 2025, 11:00 AM EST - 9 months ago

BeOne Medicines AG Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 6:00 AM EST - 9 months ago

Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

Nov 10, 2025, 9:30 AM EST - 10 months ago

BeOne Medicines AG Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 6, 2025, 8:00 AM EST - 10 months ago

BeOne Medicines AG Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:00 AM EST - 10 months ago

BeOne Medicines AG Quarterly report: Q3 2025

Nov 6, 2025, 8:00 AM EST - 10 months ago

BeOne Medicines AG Earnings release: Q3 2025

Nov 6, 2025, 8:00 AM EST - 10 months ago

BeOne Medicines AG Slides: Q3 2025

Nov 6, 2025, 6:00 AM EST - 10 months ago

BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates

Oct 22, 2025, 6:01 AM EDT - 10 months ago

BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6

Oct 20, 2025, 6:00 AM EDT - 10 months ago

BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025

Oct 13, 2025, 6:00 AM EDT - 11 months ago

BeOne Medicines' Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA

Sep 8, 2025, 1:50 PM EDT - 1 year ago

BeOne Medicines AG Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

$BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)$

Aug 29, 2025, 6:00 AM EDT - 1 year ago

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Aug 27, 2025, 6:00 AM EDT - 1 year ago

European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025

Aug 26, 2025, 6:01 AM EDT - 1 year ago

BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 25, 2025, 6:00 AM EDT - 1 year ago

BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million

RPRX

Aug 21, 2025, 6:00 AM EDT - 1 year ago

European Commission Approves Tablet Formulation of BeOne Medicines' BRUKINSA® for All Approved Indications

Aug 6, 2025, 8:00 AM EDT - 1 year ago

BeOne Medicines AG Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

BeOne Medicines AG Quarterly report: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

BeOne Medicines AG Earnings release: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

BeOne Medicines AG Slides: Q2 2025

Aug 6, 2025, 6:00 AM EDT - 1 year ago

BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates

Jul 31, 2025, 6:00 AM EDT - 1 year ago

BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom's Macroglobulinemia

Jul 28, 2025, 6:00 AM EDT - 1 year ago

BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment

Jul 16, 2025, 6:00 AM EDT - 1 year ago

BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6

Jul 10, 2025, 6:00 AM EDT - 1 year ago

European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma

Jul 9, 2025, 8:00 PM EDT - 1 year ago

Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development

Jun 26, 2025, 8:30 AM EDT - 1 year ago

BeOne Medicines AG Transcript: Status Update

Jun 26, 2025, 8:30 AM EDT - 1 year ago

BeOne Medicines AG Press release: Status Update

Jun 26, 2025, 8:30 AM EDT - 1 year ago

BeOne Medicines AG Slides: Status Update

Jun 26, 2025, 6:00 AM EDT - 1 year ago

BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day

Jun 25, 2025, 6:00 AM EDT - 1 year ago

BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®

albiegf13 Aug. 19 at 12:33 AM

$IBRX Both $AMGN & $ONC hit new all time highs today...

2 · Reply

JimmyOcarri Aug. 17 at 7:56 PM

$WDC $CIEN $STRL $ONC $IAG possible

0 · Reply

MaverikIT Aug. 11 at 2:59 PM

@Jblack500 @cynicaloptimist @WAJeff @BustaCapital @IsabellaDC @No_Face_character $SE $ONC $SKHY ... $KORU

0 · Reply

BixbyKnolls Aug. 11 at 2:45 PM

$IBRX That BeOne Medicines $ONC has the Magic touch. Chart been on the move- They signed a deal for China with $RVMD. IBRX has a collaboration with $ONC -- waiting for word.

0 · Reply

Lexcol Aug. 11 at 1:52 PM

$CMPX back to 3 $ $RVMD $ONC

0 · Reply

Pika_Capital Aug. 10 at 1:45 PM

$ONC biggest position from Cost basis perspective at the moment. Firing on all cylinders. There is china stigma attached to this name still but it's slowly fading away

0 · Reply

Zephix Aug. 7 at 10:58 AM

$ONC Got more than 50 clinical and commercial programs, including promising therapies for solid tumors, BCL-2 inhibition, and antibody-drug conjugates.…

0 · Reply

EarningsInsider Aug. 5 at 3:00 PM

https://www.marketbeat.com/earnings/reports/2026-8-5-beigene-ltd-stock-1/ $ONC BeOne Medicines Earnings Transcript

0 · Reply

StocktwitsNews Aug. 5 at 2:03 PM

ONC Q2 2026 Earnings Summary $ONC https://stocktwits.com/news/earnings/earnings/onc-q2-2026-earnings-summary/cZo4s6FRJIr

0 · Reply

Pika_Capital Aug. 5 at 2:01 PM

$ONC this stock should be $500, not $330 🤡 but I have time

1 · Reply

StocktwitsEarnings Aug. 5 at 1:05 PM

$ONC Q2 '26 Earnings Results & Recap BeOne Medicines Ltd. raised its 2026 total revenue guidance to $6.6 billion to $6.8 billion, with GAAP operating income of $1.0 billion to $1.1 billion and non-GAAP operating income of $1.7 billion to $1.8 billion.

0 · Reply

PrivateTrading Jul. 23 at 8:17 PM

$ONC An analyst from JPMorgan maintained BeOne Medicines at ’overweight’ with a price target of $425.00 from a prior price target of $415.00.

0 · Reply

BixbyKnolls Jul. 23 at 6:48 PM

$IBRX I tersting build out in Production USA- a big build but only adding 135 employees? $ONC - Collaboration on one trial that I know of.. Probably other projects..

0 · Reply

PrivateTrading Jul. 22 at 11:46 AM

$ONC An undervalued company. Market cap to Sales ratio. Sales growth. Sonrotoclax + Brukinsa will be a formidable fixed duration solution. BGB-16673 as a 2L would be a huge asset. However, I think the FDA would approve it as a 3L initially.

0 · Reply

Estimize Jul. 20 at 11:01 AM

Wall St is expecting 1.57 EPS for $ONC Q2 [Reporting 08/05 BMO] http://www.estimize.com/intro/onc?chart=historical&metric_name=eps&utm_cont

0 · Reply

MaverikIT Jul. 15 at 3:49 PM

$BABA +6.32 - some saying 'uninvestable' for china - haha $SE $ONC @G_R_

0 · Reply

notreload_ai Jul. 13 at 9:41 AM

Jefferies upgrades $ONC from Hold to Buy and raises price target to $380, implying 27% upside. Strong Brukinsa outlook and solid tumor pipeline drive bullish view. https://notreload.xyz/xy/analyst-upgrade-boosts-onc-as-brukinsa-outlook-strengthens/

0 · Reply

Pika_Capital Jul. 6 at 3:50 PM

$ONC loaded heavily under $300. One of the most mispriced bios out there

1 · Reply

Estimize Jul. 6 at 11:03 AM

Wall St is expecting 1.65 EPS for $ONC Q2 [Reporting 08/21 BMO] http://www.estimize.com/intro/onc?chart=historical&metric_name=eps&utm_cont

0 · Reply

PrivateTrading Jun. 26 at 8:02 PM

$ONC On June 26, 2026, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy and regardless of prior BTK inhibitor treatment.

0 · Reply

Estimize Jun. 22 at 11:04 AM

Wall St is expecting 1.65 EPS for $ONC Q2 [Reporting 08/21 BMO] http://www.estimize.com/intro/onc?chart=historical&metric_name=eps&utm_cont

0 · Reply

BioTechHealthX Jun. 21 at 3:13 PM

$ONC BeOne Medicines AG (ONC) has a massive $32.74 billion market capitalization, strong gross margins, and several cancer therapies targeting major unmet medical needs. Analysts remain bullish, but is this healthcare stock still flying under the radar for long-term investors? https://biotechhealthx.com/biotech-news/is-beone-medicines-onc-a-smart-biotech-stock-to-watch-for-long-term-growth/

0 · Reply

Market Cap	23.65B
Revenue (ttm)	3.81B
Net Income (ttm)	-644.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	318.72
Profit Margin	-16.92%
Debt to Equity Ratio	0.05

Volume	189,200
Avg Vol	468,388
Day's Range	N/A - N/A
Shares Out	99.25M
Stochastic %K	82%
Beta	0.35
Analysts	Strong Sell
Price Target	$321.39